Evaluation of a tolerogenic LNP (lipid nanoparticle) formulation to treat type 1 diabetes in non-obese diabetic (NOD) mice, an established mouse model of type 1 diabetes.
Integrated Nanotherapeutics Inc.
12 records totalling $1,579,150.00 CAD, from official Government of Canada open data.
Embed this chart
By department
| National Research Council Canada | $1,470,844 | 9 records |
| Western Economic Diversification Canada | $100,000 | 1 record |
| Global Affairs Canada | $8,306 | 2 records |
Records
Development of INT-101 formulation for human dosing and prevention of diabetes
This project aims to develop effective immunomodulatory formulations to induce immune tolerance as a therapeutic strategy for autoimmune and inflammatory diseases.
This project aims to develop effective immunomodulatory formulations to induce immune tolerance as a therapeutic strategy for autoimmune and inflammatory diseases.
Develop and market novel therapies for the treatment of diabetes
Development of lipid nanoparticles (LNP) encasing mRNA for vaccines.
ICAP 2022 – International Co-Innovation Action Plan
Development of immunomodulatory formulations for inflammatory diseases
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research...
The purpose of this CanExport Innovation (CXI) grant agreement is to support organizations and to build on targeted relationships between Canadian companies/researchers and key organizations in other...